Skip Navigation


Nucleic Acids Research Advance Access originally published online on September 2, 2008
Nucleic Acids Research 2008 36(17):5645-5651; doi:10.1093/nar/gkn558
This Article
Right arrow Full Text Freely available
Right arrow Print PDF (9581K) Freely available
Right arrow Screen PDF (636K) Freely available
Right arrow Supplementary Data
Right arrowOA All Versions of this Article:
36/17/5645    most recent
gkn558v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Commercial Re-use Guidelines
for Open Access NAR Content
Google Scholar
Right arrow Articles by Chillemi, G.
Right arrow Articles by Desideri, A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chillemi, G.
Right arrow Articles by Desideri, A.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nucleic Acids Research, 2008, Vol. 36, No. 17 5645-5651
© 2008 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.


Molecular Biology

Thr729 in human topoisomerase I modulates anti-cancer drug resistance by altering protein domain communications as suggested by molecular dynamics simulations

Giovanni Chillemi1,*, Ilda D’Annessa1,2, Paola Fiorani2, Carmen Losasso3, Piero Benedetti3 and Alessandro Desideri2,4

1CASPUR Inter-University Consortium for the Application of Super-Computing for Universities and Research, Via dei Tizii 6, Rome 00185, 2Department of Biology and Centro di Bioinformatica e Biostatistica, University of Rome Tor Vergata, Via Della Ricerca Scientifica, Rome 00133, 3Department of Biology, University of Padua, Via U. Bassi 58/B, Padua 35131 and 4National Institute for Infectious Diseases ‘L. Spallanzani’, Via Portuense 292, Rome 00149, Italy

*To whom correspondence should be addressed. Tel: +39 06 4486706; Fax: +39 06 4957083; Email: g.chillemi{at}caspur.it

Received June 10, 2008. Revised August 18, 2008. Accepted August 18, 2008.

The role of Thr729 in modulating the enzymatic function of human topoisomerase I has been characterized by molecular dynamics (MD) simulation. In detail, the structural–dynamical behaviour of the Thr729Lys and the Thr729Pro mutants have been characterized because of their in vivo and in vitro functional properties evidenced in the accompanying paper. Both mutants can bind to the DNA substrate and are enzymatically active, but while Thr729Lys is resistant even at high concentration of the camptothecin (CPT) anti-cancer drug, Thr729Pro shows only a mild reduction in drug sensitivity and in DNA binding. MD simulations show that the Thr729Lys mutation provokes a structural perturbation of the CPT-binding pocket. On the other hand, the Thr729Pro mutant maintains the wild-type structural scaffold, only increasing its rigidity. The simulations also show the complete abolishment, in the Thr729Lys mutant, of the protein communications between the C-terminal domain (where the active Tyr723 is located) and the linker domain, that plays an essential role in the control of the DNA rotation, thus explaining the distributive mode of action displayed by this mutant.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.